Add to ORKGAim of the Study Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers with poor prognosis and unfavorable clinicopathological characteristics. Until now, its prognostic value has never been studied in pancreatic ductal adenocarcinoma (PDAC). The aim of this study was to investigate podocalyxin expression in PDAC by a novel monoclonal antibody and a commercially available polyclonal antibody. Patients and Materials With tissue microarrays and immuno-histochemistry, podocalyxin expression evaluation in-volved 168 PDAC patients. The associa-tions of the podocalyxin tumor expression with clinicopathological variables were explored by Fisher’s exact test and the linear-by-linear test. Survival analy...
Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigate...
<p>Cancer-specific survival analysis according to the Kaplan-Meier method for membranous PODXL expre...
The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...
Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers ...
Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive tumor phenotyp...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has...
Full list of author information is available at the end of the articleBackground Pancreatic cancer i...
Colorectal cancer (CRC) is the third most common cancer worldwide with more than 700,000 deaths ever...
Oral cancers constitute approximately 2% of all cancers, with the most common histological type bein...
Adenocarcinoma of the periampullary region is associated with poor prognosis and new prognostic and ...
Background: Podocalyxin-like protein (PODXL) is a cell surface transmembrane glycoprotein, the expre...
Introduction: Podocalyxin (gene name PODXL) is a CD34-related sialomucin implicated...
Copyright © 2015 Anna S. Gerdtsson et al. This is an open access article distributed under the Creat...
Background: Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a rol...
Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigate...
<p>Cancer-specific survival analysis according to the Kaplan-Meier method for membranous PODXL expre...
The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...
Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in many cancers ...
Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein associated with aggressive tumor phenotyp...
The advent of targeted therapies has vastly improved cancer diagnostics and treatments over the last...
Background: Podocalyxin-like 1 (PODXL) is a cell-adhesion glycoprotein and stem cell marker that has...
Full list of author information is available at the end of the articleBackground Pancreatic cancer i...
Colorectal cancer (CRC) is the third most common cancer worldwide with more than 700,000 deaths ever...
Oral cancers constitute approximately 2% of all cancers, with the most common histological type bein...
Adenocarcinoma of the periampullary region is associated with poor prognosis and new prognostic and ...
Background: Podocalyxin-like protein (PODXL) is a cell surface transmembrane glycoprotein, the expre...
Introduction: Podocalyxin (gene name PODXL) is a CD34-related sialomucin implicated...
Copyright © 2015 Anna S. Gerdtsson et al. This is an open access article distributed under the Creat...
Background: Overexpression of the transmembrane sialomucin podocalyxin, which is known to play a rol...
Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigate...
<p>Cancer-specific survival analysis according to the Kaplan-Meier method for membranous PODXL expre...
The outcome of periampullary adenocarcinomas remains poor with few treatment options. Podocalyxin-li...